Standardization and quality control studies of 'real-time'quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease …
J Gabert, E Beillard, VHJ Van der Velden, W Bi… - Leukemia, 2003 - nature.com
Detection of minimal residual disease (MRD) has proven to provide independent prognostic
information for treatment stratification in several types of leukemias such as childhood acute …
information for treatment stratification in several types of leukemias such as childhood acute …
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
BJ Druker, NB Lydon - The Journal of clinical investigation, 2000 - Am Soc Clin Investig
AProtein kinase targeted. A number of these molecules are broad-spectrum kinase
inhibitors. BStaurosporine class represents examples of broad-spectrum kinase inhibitors …
inhibitors. BStaurosporine class represents examples of broad-spectrum kinase inhibitors …
Minimal residual disease in leukaemia patients
T Szczepariski, A Orfão, VHJ van der Valden… - The lancet …, 2001 - thelancet.com
Because of developments in diagnosis of haemopoietic malignant diseases during the past
two decades, routine and reliable identification of very low numbers of malignant cells …
two decades, routine and reliable identification of very low numbers of malignant cells …
Comparison of chromosome banding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic …
C Schoch, S Schnittger, S Bursch, D Gerstner… - Leukemia, 2002 - nature.com
For the diagnosis of CML and for monitoring of treatment response the detection of the t (9;
22)(q34; q11) or the BCR-ABL rearrangement is necessary. Chromosome banding analysis …
22)(q34; q11) or the BCR-ABL rearrangement is necessary. Chromosome banding analysis …
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
An analysis was performed of the response to treatment with donor lymphocyte infusions
(DLI) and the survival in 66 consecutive patients who relapsed after primary treatment by …
(DLI) and the survival in 66 consecutive patients who relapsed after primary treatment by …
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase–polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for …
E Olavarria, E Kanfer, R Szydlo, J Kaeda… - Blood, The Journal …, 2001 - ashpublications.org
The reverse transcriptase–polymerase chain reaction (RT-PCR) has become widely used
for monitoring minimal residual disease after allogeneic stem cell transplantation (SCT) for …
for monitoring minimal residual disease after allogeneic stem cell transplantation (SCT) for …
[HTML][HTML] Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone …
NP Murray, S Aedo, C Fuentealba… - Asian Pacific Journal …, 2022 - ncbi.nlm.nih.gov
Results: 402 men underwent radical prostatectomy, one month post surgery 79 men were
positive for only bone marrow micro-metastasis and formed the study group; of whom 36/79 …
positive for only bone marrow micro-metastasis and formed the study group; of whom 36/79 …
Detection of minimal residual disease
G Dölken - 2001 - Elsevier
A high percentage of patients with leukemia, lymphoma, and solid tumors achieve a
complete clinical remission after initial treatment, but the majority of these patients will finally …
complete clinical remission after initial treatment, but the majority of these patients will finally …
[HTML][HTML] The possible role of matrix metalloprotienase-2 in the relapse in patients with stage II colon cancer treated by curative surgery
NP Murray, R Villalon, S Aedo… - Asian Pacific Journal …, 2023 - ncbi.nlm.nih.gov
Aims: To determine the association of micro-metastatic matrix metalloproteinase-2 (MMP-2)
expression, the absolute lymphocyte count (ALC)) and outcome in stage II colon cancer …
expression, the absolute lymphocyte count (ALC)) and outcome in stage II colon cancer …
Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy
E Pertusini, J Ratajczak, M Majka… - Blood, The Journal …, 2001 - ashpublications.org
Paclitaxel and carboplatin chemotherapy is reported to be a platelet-sparing drug
combination. This study investigated potential mechanisms for this observation by studying …
combination. This study investigated potential mechanisms for this observation by studying …